MX361342B - Composiciones y metodos para formulaciones de alfavirus vivos atenuados. - Google Patents
Composiciones y metodos para formulaciones de alfavirus vivos atenuados.Info
- Publication number
- MX361342B MX361342B MX2015012894A MX2015012894A MX361342B MX 361342 B MX361342 B MX 361342B MX 2015012894 A MX2015012894 A MX 2015012894A MX 2015012894 A MX2015012894 A MX 2015012894A MX 361342 B MX361342 B MX 361342B
- Authority
- MX
- Mexico
- Prior art keywords
- live
- compositions
- attenuated
- methods
- attenuated alphavirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para alfavirus vivos atenuados. En ciertas modalidades, una composición de virus vivo atenuado incluye, pero no se limita a, uno o más alfavirus vivosatenuados y composiciones para reducir la inactivación y/o degradación del alfavirus vivo atenuado. En otras modalidades, la composición de virus vivo atenuado puede ser una composición de vacuna. En otras composiciones, una composición de alfavirus vivo atenuado puede incluir tampón de HEPES. En otras modalidades, el tampón de HEPES puede incluir además un carbohidrato y gelatina y/o una sal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784122P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/026570 WO2014151855A1 (en) | 2013-03-14 | 2014-03-13 | Compositions and methods for live, attenuated alphavirus formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015012894A MX2015012894A (es) | 2016-04-04 |
MX361342B true MX361342B (es) | 2018-12-04 |
Family
ID=50489420
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012894A MX361342B (es) | 2013-03-14 | 2014-03-13 | Composiciones y metodos para formulaciones de alfavirus vivos atenuados. |
MX2018014977A MX2018014977A (es) | 2013-03-14 | 2015-09-14 | Composiciones y metodos para formulaciones de alfavirus vivos atenuados. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014977A MX2018014977A (es) | 2013-03-14 | 2015-09-14 | Composiciones y metodos para formulaciones de alfavirus vivos atenuados. |
Country Status (20)
Country | Link |
---|---|
US (2) | US10137186B2 (es) |
EP (2) | EP2968515B1 (es) |
JP (3) | JP6426695B2 (es) |
KR (1) | KR20160003662A (es) |
CN (2) | CN111729077A (es) |
AP (1) | AP2015008733A0 (es) |
AU (2) | AU2014236804B2 (es) |
BR (1) | BR112015023205A2 (es) |
CA (1) | CA2903711A1 (es) |
CR (1) | CR20150553A (es) |
DO (1) | DOP2015000226A (es) |
EC (1) | ECSP20007842A (es) |
HK (1) | HK1220358A1 (es) |
MX (2) | MX361342B (es) |
MY (1) | MY178476A (es) |
NZ (1) | NZ631012A (es) |
PH (1) | PH12015502115A1 (es) |
SG (3) | SG10201909051QA (es) |
TW (2) | TWI649087B (es) |
WO (1) | WO2014151855A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI649087B (zh) | 2013-03-14 | 2019-02-01 | 武田疫苗股份有限公司 | 用於活減毒阿爾法病毒配方之組成物及方法 |
EP3087188A1 (en) | 2013-12-23 | 2016-11-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
CA3019529A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Vaccines, Inc. | Compositions and methods for stabilizing alphaviruses with improved formulations |
NL2022538B1 (en) * | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
JPWO2022158097A1 (es) * | 2021-01-19 | 2022-07-28 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
RU2035508C1 (ru) * | 1991-08-16 | 1995-05-20 | Институт органической химии СО РАН | Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей |
US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
AU4594996A (en) * | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6465634B1 (en) * | 1996-04-05 | 2002-10-15 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
EP1100944A1 (en) * | 1998-07-30 | 2001-05-23 | The Johns Hopkins University School Of Medicine | Targeted alphavirus and alphaviral vectors |
US6869907B2 (en) * | 2000-05-02 | 2005-03-22 | Pentax Corporation | Color-image-forming medium |
FR2814957B1 (fr) | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
CA2469491A1 (en) * | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
EP2591771A1 (en) * | 2002-04-11 | 2013-05-15 | MedImmune, LLC | Preservation of bioactive materials by freeze dried foam |
CN1893973B (zh) | 2003-12-17 | 2010-12-08 | 惠氏公司 | 产生储存稳定病毒及其免疫原性组合物的方法 |
BRPI0716145B1 (pt) * | 2006-09-01 | 2021-06-22 | Bharat Biotech International Limited | Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya |
WO2008058035A1 (en) * | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
AU2007317847B2 (en) | 2006-11-07 | 2013-10-31 | Sanofi Pasteur Biologics, Llc | Stabilization of vaccines by lyophilization |
MY180465A (en) | 2007-04-06 | 2020-11-30 | Takeda Vaccines Inc | Methods and compositions for live attenuated viruses |
CN101835488B (zh) | 2007-09-04 | 2018-10-26 | 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) | 轮状病毒的热灭活 |
KR20160005378A (ko) | 2007-09-14 | 2016-01-14 | 사노피 파스테르 바이오로직스, 엘엘씨 | 클로스트리듐 디피실리 톡소이드 a 및 b를 포함하는 약학적 조성물 |
JP5758632B2 (ja) | 2008-01-24 | 2015-08-05 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 |
NZ593220A (en) | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
WO2011090712A2 (en) | 2009-12-28 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
WO2011151726A2 (en) * | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
TWI649087B (zh) * | 2013-03-14 | 2019-02-01 | 武田疫苗股份有限公司 | 用於活減毒阿爾法病毒配方之組成物及方法 |
-
2014
- 2014-03-13 TW TW103109097A patent/TWI649087B/zh not_active IP Right Cessation
- 2014-03-13 SG SG10201909051Q patent/SG10201909051QA/en unknown
- 2014-03-13 KR KR1020157029550A patent/KR20160003662A/ko not_active Application Discontinuation
- 2014-03-13 TW TW107130863A patent/TW201900192A/zh unknown
- 2014-03-13 MX MX2015012894A patent/MX361342B/es active IP Right Grant
- 2014-03-13 EP EP14717940.2A patent/EP2968515B1/en active Active
- 2014-03-13 SG SG10201801459SA patent/SG10201801459SA/en unknown
- 2014-03-13 CA CA2903711A patent/CA2903711A1/en not_active Abandoned
- 2014-03-13 NZ NZ631012A patent/NZ631012A/en not_active IP Right Cessation
- 2014-03-13 CN CN202010573138.6A patent/CN111729077A/zh active Pending
- 2014-03-13 JP JP2016502179A patent/JP6426695B2/ja not_active Expired - Fee Related
- 2014-03-13 AP AP2015008733A patent/AP2015008733A0/xx unknown
- 2014-03-13 SG SG11201507462QA patent/SG11201507462QA/en unknown
- 2014-03-13 BR BR112015023205A patent/BR112015023205A2/pt not_active IP Right Cessation
- 2014-03-13 WO PCT/US2014/026570 patent/WO2014151855A1/en active Application Filing
- 2014-03-13 MY MYPI2015002316A patent/MY178476A/en unknown
- 2014-03-13 US US14/209,921 patent/US10137186B2/en not_active Expired - Fee Related
- 2014-03-13 AU AU2014236804A patent/AU2014236804B2/en not_active Ceased
- 2014-03-13 EP EP19172758.5A patent/EP3603667A1/en not_active Withdrawn
- 2014-03-13 CN CN201480018785.3A patent/CN105377293B/zh not_active Expired - Fee Related
-
2015
- 2015-09-09 DO DO2015000226A patent/DOP2015000226A/es unknown
- 2015-09-14 MX MX2018014977A patent/MX2018014977A/es unknown
- 2015-09-14 PH PH12015502115A patent/PH12015502115A1/en unknown
- 2015-10-14 CR CR20150553A patent/CR20150553A/es unknown
-
2016
- 2016-07-15 HK HK16108388.5A patent/HK1220358A1/zh unknown
-
2018
- 2018-10-01 AU AU2018236897A patent/AU2018236897B2/en not_active Ceased
- 2018-10-12 US US16/159,221 patent/US10806781B2/en active Active
- 2018-10-25 JP JP2018200754A patent/JP6761015B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-31 EC ECSENADI20207842A patent/ECSP20007842A/es unknown
- 2020-09-03 JP JP2020148154A patent/JP2020193231A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
CL2016001547A1 (es) | Composiciones para el cuidado oral | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
GB2535876A (en) | Absorbent clumping animal litter compositions | |
MX359999B (es) | Vacunas de virus bovino liquidas estables. | |
MX2016004556A (es) | Composicion de hueso comprimido y metodo para usar la misma. | |
PH12019501722A1 (en) | Compositions and methods for promoting hair growth with mpc1 inhibitors | |
PH12017500627A1 (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
MX2016007316A (es) | Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli. | |
MX2019010101A (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
MX2016012112A (es) | Feromona tranquilizadora para gatos. | |
MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
PH12018502119A1 (en) | Compositions and methods for stabilizing alphaviruses with improved formulations | |
EA201591867A1 (ru) | Композиция лютеина, подходящая для составов детского питания | |
MX2016011572A (es) | Composiciones antimicrobianas de acido organico. | |
MX2017014971A (es) | Composiciones de sal mejoradas y metodo de preparacion de las mismas. | |
MX2014015767A (es) | Composiciones de etanol producidas termoquimicamente. | |
IN2014MU00284A (es) | ||
WO2018175580A3 (en) | Development of an alternative modified live influenza b virus vaccine | |
MX2016001694A (es) | Formulacion de vacuna de sacarido. | |
NZ708737A (en) | Thrombin solution and methods of use thereof | |
TH179835A (th) | องค์ประกอบและวิธีการสำหรับสูตรตำรับอัลฟาไวรัสซึ่งถูกทำให้อ่อนฤทธิ์ที่มีชีวิต |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |